Jennifer A. Woyach, MD, Discusses Use of Ibrutinib in CLL at 2021 ASH

News
Video

Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.

During the 2021 American Society of Hematology Annual Meeting, Jennifer A. Woyach, MD, associate professor in the Division of Hematology at The Ohio State University, discussed the benefits of treating patients with newer agents, such as the Bruton tyrosine kinase inhibitor ibrutinib [Imbruvica], over chemoimmunotherapy. During the meeting, she is presenting data on ibrutinib-containing regimens in patients 65 years or older, which has been shown to be superior to treatment with bendamustine plus rituximab.

Transcript:

I hope that this continues to make practitioners choose novel therapies for their patients over chemoimmunotherapy. I think there are some special situations where chemoimmunotherapy is still appropriate, but for most patients, they will do better with Bruton’s tyrosine kinase [BTK] inhibitors or with venetoclax [Venclexta] plus obintuzumab [Gazyva] as opposed to a chemoimmunotherapy regimen. The other big thing that we’ve seen from [the phase 3 AO41202 (NCT01886872) trial], and has been shown from other trials in the frontline setting, is that TP53 abnormalities especially don’t make a difference in outcomes with ibrutinib at this time point at least. Patients with or without 17p deletion, with or without TP53 mutation will likely derive the same benefit from ibrutinib. This does set this drug apart from some other classes of medications, even among the novel agents.

Reference

Woyach JA, Ruppert AS, Heerema NA, et al. Long-term results of Alliance AO41202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-13, 2021; Atlanta, GA. Accessed December 6, 2021. https://bit.ly/31EcBlO

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content